No one should have to suffer with opioid addiction. In a sent yesterday to the U.S. Food and Drug Administration (FDA), 熊猫视频outlined strategies that can assist in the development of future research and clinical guidance as part of the fight against the opioid crisis. The letter was in response to a call for comments on a public workshop entitled, 鈥�.鈥�
In the comment letter, 熊猫视频notes that opioid addiction may begin with a prescription by a clinician intended to help patients manage pain. As part of the solution, 熊猫视频points to the need for evidence-based, patient-centered care, stating, 鈥淭here is no simple formula or one-size-fits-all approach to differentiate safe or unsafe opioid prescriptions.鈥�
熊猫视频also calls for more research efforts from stakeholders like the FDA and the National Institutes of Health on areas including:
- Comparative effectiveness studies of prescription opioids including dosages
- Formulations for different types of pain (e.g., acute versus chronic pain)
- Evaluating non-opioid and non-pharmacological treatment modalities to manage various types of pain
The letter closes with AHIP鈥檚 health insurance provider members鈥� continued commitment to assist the FDA in its efforts to promote appropriate access to pain care and prevent opioid addiction.